Mounjaro
Signals mentioning Mounjaro
- Mounjaro overtakes legacy medicines to become India’s top-selling drug
- India’s GLP-1 market stabilises as generic semaglutide boom fades
- Mounjaro sales jump 502% to ₹1,256 crore as GLP-1 demand accelerates in India
- Tata Consumer readies nutrition products for India’s GLP-1 weight-loss drug users
- Cipla prioritises Yurpeak as sales nearly double, delaying semaglutide launch
- Cipla’s India sales rise 12% as it leans on consumer-health expansion
- Dove's Real Beauty playbook collides with the Ozempic era